|1.||Brewer, George J: 34 articles (10/2014 - 01/2002)|
|2.||Merajver, Sofia D: 15 articles (04/2013 - 03/2002)|
|3.||Dick, Robert: 13 articles (06/2009 - 03/2003)|
|4.||Hou, Guoqing: 10 articles (03/2010 - 11/2005)|
|5.||Pan, Quintin: 10 articles (01/2010 - 09/2002)|
|6.||Teknos, Theodoros N: 5 articles (01/2010 - 07/2003)|
|7.||Singh, Rakesh K: 4 articles (01/2015 - 05/2011)|
|8.||Askari, Fred: 4 articles (03/2010 - 03/2003)|
|9.||Dick, Robert B: 4 articles (03/2010 - 03/2003)|
|10.||Zeng, Chunhua: 4 articles (08/2008 - 05/2006)|
|1.||Hepatolenticular Degeneration (Wilson's Disease)
02/10/2009 - "Tetrathiomolybdate (TTM) is a promising new treatment for Wilson's disease which has been demonstrated both in an animal model and in clinical trials. "
05/01/1992 - "A new experimental drug, tetrathiomolybdate, shows promise in the initial treatment of patients with Wilson disease. "
05/01/2004 - "Studies of the use of ammonium tetrathiomolybdate as an alternative chelating agent for the initial treatment of neurologic Wilson's disease are still in the experimental phase. "
03/01/2003 - "Open-label study of 55 untreated patients (22 of them new) presenting with neurologic Wilson disease treated with tetrathiomolybdate varying from 120 to 410 mg/d for 8 weeks and then followed up for 3 years. "
10/01/2014 - "Tetrathiomolybdate (TM) is a unique anticopper drug developed for the treatment of the neurologic presentation of Wilson's disease, for which it is excellent. "
01/01/2015 - "Tetrathiomolybdate (TM) is a potent anti-cancer and anti-angiogenic agent and has been investigated in a number of clinical trials for cancer. "
12/01/2007 - "This study examines the target specificity of tetrathiomolybdate (ATM), an anti-angiogenic, anti-tumor agent against the viability / proliferation of arterial, venous, capillary endothelial and tumor cells. "
01/01/2000 - "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study."
12/01/2007 - "Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells."
03/01/2006 - "The tetrathiomolybdate + RT combined therapy group of mice showed a statistically significant decrease in tumor growth compared with both the tetrathiomolybdate alone (P = .001) and RT alone groups (P<.001). "
05/01/2008 - "Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis."
12/01/2004 - "Results in mice injected endotracheally with bleomycin confirmed that tetrathiomolybdate therapy was effective in reducing fibrosis. "
06/01/2009 - "It is clear from this animal study that dissolution of preexisting fibrosis can be strongly catalyzed by lowering copper levels with tetrathiomolybdate. "
06/01/2009 - "Thus, in this study, we produced hepatic fibrosis in mice by treatment with carbon tetrachloride, then gave half the fibrotic mice tetrathiomolybdate for 3 months, while the other half of the fibrotic mice received nothing for 3 months and served as controls. "
12/01/2004 - "This indicates that tetrathiomolybdate therapy can be effective even when fibrosis is at a more chronic stage, wherein inflammatory cytokines are playing a diminishing role. "
|4.||Breast Neoplasms (Breast Cancer)
01/01/2010 - "Our study aimed 1) to investigate the mechanism by which cooperation between Mphi and aggressive breast cancer cells (MDA-MB-231) induces angiogenesis; 2) to examine the effect of tetrathiomolybdate (TM) on this angiogenic activity. "
01/01/2010 - "Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate."
06/01/2013 - "This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence. "
06/01/2013 - "Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse."
10/06/2015 - "To investigate: a) whether sub-toxic DSF efficacy can be increased without Cu overload against human melanoma cells with unequal BRAF(V600E) mutant status and Her2-overexpressing SKBR3 breast cancer cells, by increasing H2O2from exogenous SOD; b) to compare the anti-tumor efficacy of DSF with that of another clinically used copper chelator, tetrathiomolybdate (TTM). "
|5.||Prostatic Neoplasms (Prostate Cancer)
09/01/2002 - "Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. "
01/01/2006 - "Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer."
|6.||Carbon Tetrachloride (Tetrachloromethane)
|8.||Hydroxyproline (4 Hydroxyproline)
|10.||Reactive Oxygen Species (Oxygen Radicals)
|2.||Chelation Therapy (Therapy, Chelation)
|4.||Heterologous Transplantation (Xenotransplantation)